Overland ADCT BioPharma (CN)

Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics, is developing and commercializing four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors – loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 – in greater China and Singapore. *

	Start	2021-04-06 existent jv
	Group	Overland Pharmaceuticals (Group)
	Industry	antibody-drug conjugate (ADC)
	Industry 2	loncastuximab tesirine-lpyl (ADCT-402)
	Person	Koo, Eric (Overland Pharmaceuticals 202104– CEO of Overland ADCT BioPharma before Takeda China + MSC Taiwan + Bayer)

	Region	Shanghai
	Country	China
	City	n. a.
		Address record changed: 2021-04-09

Basic data	Employees	n. a.

		* Document for »About Section«: ADC Therapeutics S.A.. (4/6/21). "Press Release: Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer". Boston, MA, Shanghai & Lausanne.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Overland Pharmaceuticals (Group)

[1] ADC Therapeutics S.A.. (4/6/21). "Press Release: Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer". Boston, MA, Shanghai & Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]